RxDoctor Payments Data

Jose Torreblanca, MD

Family Medicine · South Gate, CANPI 1407922107

Payments from drug & device makers

$4,614in general payments, 2019–2025

Across 163 payments — averaging $28.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$817
  • Lilly USA, LLC$616
  • Bayer$533
  • Abbott$433
  • Boehringer Ingelheim$330
  • AstraZeneca$256
  • plus $2K from 22 others

What the payments were for

  • Travel & lodging$60%
  • Food & beverage$4,608100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,614 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$45,508
Medicare patients
133
Services billed
862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone55$42,572
JardianceEmpagliflozin35$37,409
TrulicityDulaglutide28$30,844
FarxigaDapagliflozin Propanediol30$29,123
EliquisApixaban41$28,263
OzempicSemaglutide23$28,191
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog82$26,297
JanuviaSitagliptin Phosphate23$21,552
Lantus SolostarInsulin Glargine,hum.Rec.Anlog149$16,734
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$13,884
Humalog Kwikpen U-100Insulin Lispro64$10,842
JanumetSitagliptin Phos/Metformin Hcl13$8,981
Tresiba Flextouch U-200Insulin Degludec11$8,149
Nano 2nd Gen Pen NeedlePen Needle, Diabetic143$8,132
InvokanaCanagliflozin11$5,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$533$42,57255 claims
Boehringer IngelheimJardiance$330$37,40935 claims
Lilly USA, LLCTrulicity$616$30,84428 claims
MerckJanuvia, Janumet$150$30,53336 claims
AstraZenecaFarxiga$256$29,12330 claims
PfizerEliquis$42$28,26341 claims
Novo NordiskOzempic$817$28,19123 claims
Johnson & JohnsonInvokana$30$5,88611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in South Gate

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →